Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Weight-loss injections are dominating the market: Where will GLP-1 pills fit in? Glucagon-like peptide-1 (GLP-1) medications have emerged as powerful tools for weight loss. So far, injectable options ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial with injectable compound and a syringe. - Anna Hoychuk // Shutterstock Compounded semaglutide is a medication that’s custom ...

Semaglutide has already become more than just a “vanity drug.” Clinical trials like SUSTAIN-6 and FLOW have shown it can slash the risk of kidney disease, reduce major heart attacks, and even lower ...

The drug behind Ozempic has been found to restore joint cartilage in osteoarthritis, through a mechanism that works independently of weight loss.

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

Semaglutide's patent expiry in India could sharply reduce the cost of popular weight-loss and diabetes injections.

Indian drugmaker Dr Reddy's Laboratories is likely to launch its generic semaglutide injection in the country in March ​under ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...